Cramer's 'Mad Money' Recap: Bright Spots

Search Jim Cramer's "Mad Money" trading recommendations using our exclusive "Mad Money" Stock Screener.

NEW YORK ( TheStreet) -- With the markets geared for disappointment, most investors are expecting the worst, Jim Cramer told "Mad Money" viewers Wednesday.

But that doesn't mean that there aren't bright spots in the market, he continued, stocks like Stryker ( SYK), Seagate ( STX) and even Alcoa ( AA), all of which were all able to surprise Wall Street to the upside.

That's why Cramer continued his week-long series of macro themes that will trump no matter what negativity 2013 may throw at us. Tonight's themes included aerospace and China.

Despite a string of problems with Boeing's ( BA) 787 Dreamliner this week, Cramer said the need for new planes is still in full effect. Alcoa mentioned during its conference call that there are still some 8,900 planes on order because for the first time in many years airlines have the financing available to buy them.

That's why Cramer said he's buying more United Technologies ( UTX), a stock he owns for his charitable trust, Action Alerts PLUS , but he also likes Honeywell ( HON).

Then there's China, a country that's accelerating its expansion after a year of focusing on the wrong metric of interest rates. Cramer said that Joy Global ( JOY) remains a popular China play, but he's still a fan of the iShares FTSE China 25 ( FXI) ETF as it offers a basket of Chinese stocks, making it easier to invest.

Cramer said either of these two themes would make excellent investments on the next big down day for the markets.

Executive Decision

In the "Executive Decision" segment, Cramer spoke with Dr. Ron Cohen, president and CEO of Acorda Therapeutics ( ACOR), a biotech firm whose drug Ampyra is helping those with muscular sclerosis regain their mobility. Shares of Acorda are up 15% since Cramer last spoke with Cohen in July.

Cohen said that so far about 70,000 patients with MS have tried Ampyra and are having great success, but there are still an estimated 130,000 more who have walking disabilities that can benefit from the drug. Acorda is also in clinical trials testing Ampyra for other indications including cerebral palsy and chronic stroke.

If you liked this article you might like

These Stocks Are Ready to Reverse Course

Don't Get Out of Joint

Zimmer Biomet: Cramer's Top Takeaways

Market Stands at a Make-Or-Break Level: Cramer's 'Mad Money' Recap (Monday 7/17/17)

Analyst Says Rival Bidder Could Emerge for Novadaq After Stryker Deal